Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-25-014232·Lomond Therapeutics Holdings, Inc.
Schedule 13G ownership disclosure
Lomond Therapeutics Holdings, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 54173L101
Event date: 2024-12-31
- Filing-level shares
- 1,187,500.00
- Percent of class
- 4.0%
- Mark N. Tompkins
Shares: 1,187,500.00 · Class: 4.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-014232
- Form type
- SCHEDULE 13G/A
- Filer
- Lomond Therapeutics Holdings, Inc.
- CIK
- CIK 1900520
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership